Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells

Experimental Cell Research

Volumn 335, Issue 2, 2015, Pages 238-247

  Nair, Anand R ^a   Ebenezer, Philip J ^a   Saini, Yogesh ^a   Francis, Joseph ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Angiotensin II; HMGB1; Hypertensive renal injury; Inflammation; Reactive oxygen species; TLR4

Indexed keywords

ANGIOTENSIN II; CELL EXTRACT; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; LOSARTAN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SUPEROXIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT; HBP1 PROTEIN, RAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TLR4 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; ELECTRON SPIN RESONANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE SILENCING; HYPERTENSION; IMMUNOBLOTTING; KIDNEY TUBULE CELL; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL LINE; CHEMICALLY INDUCED; COMPLICATION; EPITHELIUM CELL; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULE; METABOLISM; PATHOLOGY;

RATTUS;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL LINE; EPITHELIAL CELLS; HMGB1 PROTEIN; HYPERTENSION; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; LOSARTAN; NF-KAPPA B; RATS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84937635076     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.05.011     Document Type: Article

References (72)

1. Ong K.L., Tso A.W., Lam K.S., Cheung B.M. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 2008, 51:1142-1148.
2. Gillespie C.D., Hurvitz K.A. Prevalence of hypertension and controlled hypertension-United States, 2007-2010. MMWR Surveill. Summ. 2013, 62(Suppl 3):144-148.
3. Otaki Y., Watanabe T., Takahashi H., Narumi T., Kadowaki S., et al. Association of renal tubular damage with cardio-renal anemia syndrome in patients with heart failure. Int. J. Cardiol. 2014, 173:222-228.
4. Hayden M.R., Banks W.A., Shah G.N., Gu Z., Sowers J.R. Cardiorenal metabolic syndrome and diabetic cognopathy. Cardiorenal Med. 2013, 3:265-282.
5. Cho E., Kim M., Ko Y.S., Lee H.Y., Song M., et al. Role of inflammation in the pathogenesis of cardiorenal syndrome in a rat myocardial infarction model. Nephrol. Dial. Transplant. 2013, 28:2766-2778.
6. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006, 11:36-41.
7. Cardinale J.P., Sriramula S., Pariaut R., Guggilam A., Mariappan N., et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010, 56:437-444.
8. Elks C.M., Mariappan N., Haque M., Guggilam A., Majid D.S., et al. Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am. J. Physiol. Renal Physiol. 2009, 296:F298-F305.
9. Moubarak M., Jabbour H., Smayra V., Chouery E., Saliba Y., et al. Cardiorenal syndrome in hypertensive rats: microalbuminuria, inflammation and ventricular hypertrophy. Physiol. Res. 2012, 61:13-24.
10. Tbahriti H.F., Messaoudi A., Kaddous A., Bouchenak M., Mekki K. [The degree of chronic renal failure is associated with the rate of pro-inflammatory cytokines, hyperhomocysteinemia and with oxidative stress]. Ann. Cardiol. Angeiol. (Paris) 2014, 63:135-139.
11. Macisaac R.J., Ekinci E.I., Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am. J. Kidney Dis. 2014, 63:S39-S62.
12. Janda K., Krzanowski M., Dumnicka P., Kusnierz-Cabala B., Krasniak A., et al. Transforming growth factor beta 1 as a risk factor for cardiovascular diseases in end-stage renal disease patients treated with peritoneal dialysis. Clin. Lab. 2014, 60:1163-1168.
13. Eriguchi M., Tsuruya K., Haruyama N., Yamada S., Tanaka S., et al. Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int. 2014.
14. Kang Y.M., Gao F., Li H.H., Cardinale J.P., Elks C., et al. NF-kappaB in the paraventricular nucleus modulates neurotransmitters and contributes to sympathoexcitation in heart failure. Basic Res. Cardiol. 2011, 106:1087-1097.
15. Kang Y.M., Ma Y., Zheng J.P., Elks C., Sriramula S., et al. Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc. Res. 2009, 82:503-512.
16. Nair A.R., Masson G.S., Ebenezer P.J., Del Piero F., Francis J. Role of TLR4 in lipopolysaccharide-induced acute kidney injury: protection by blueberry. Free Radic. Biol. Med. 2014, 71:16-25.
17. Cunningham P.N., Wang Y., Guo R., He G., Quigg R.J. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J. Immunol. 2004, 172:2629-2635.
18. Nitschke M., Wiehl S., Baer P.C., Kreft B. Bactericidal activity of renal tubular cells: the putative role of human beta-defensins. Exp. Nephrol. 2002, 10:332-337.
19. Shahin R.D., Engberg I., Hagberg L., Svanborg Eden C. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J. Immunol. 1987, 138:3475-3480.
20. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004, 5:825-830.
21. Dumitriu I.E., Baruah P., Valentinis B., Voll R.E., Herrmann M., et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 2005, 174:7506-7515.
22. Doi K., Ishizu T., Tsukamoto-Sumida M., Hiruma T., Yamashita T., et al. The high-mobility group protein B1-Toll-like receptor 4 pathway contributes to the acute lung injury induced by bilateral nephrectomy. Kidney Int. 2014, 86:316-326.
23. Magna M., Pisetsky D.S. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol. Med. 2014, 20:138-146.
24. Zhao H., Perez J.S., Lu K., George A.J., Ma D. Role of Toll-like receptor-4 in renal graft ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 2014, 306:F801-F811.
25. Yang S., Xu L., Yang T., Wang F. High-mobility group box-1 and its role in angiogenesis. J. Leukoc. Biol. 2014, 95:563-574.
26. Kim S.Y., Koo J.E., Seo Y.J., Tyagi N., Jeong E., et al. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br. J. Pharmacol. 2013, 168:1933-1945.
27. Masson G.S., Nair A.R., Dange R.B., Silva-Soares P.P., Michelini L.C., et al. Toll-like receptor 4 promotes autonomic dysfunction, inflammation and microglia activation in the hypothalamic paraventricular nucleus: role of endoplasmic reticulum stress. PLoS One 2015, 10:e0122850.
28. Kokkola R., Sundberg E., Ulfgren A.K., Palmblad K., Li J., et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 2002, 46:2598-2603.
29. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
30. Volz H.C., Seidel C., Laohachewin D., Kaya Z., Muller O.J., et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic Res. Cardiol. 2010, 105:805-820.
31. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Yamada S., et al. Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am. J. Med. Sci. 2012, 343:46-51.
32. Yang F., Huang X.R., Chung A.C., Hou C.C., Lai K.N., et al. Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J. Pathol. 2010, 221:390-401.
33. Rice E.K., Tesch G.H., Cao Z., Cooper M.E., Metz C.N., et al. Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney Int. 2003, 63:1265-1275.
34. Luo Y., Chihara Y., Fujimoto K., Sasahira T., Kuwada M., et al. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur. J. Cancer 2013, 49:741-751.
35. Nair A.R., Elks C.M., Vila J., Del Piero F., Paulsen D.B., et al. A blueberry-enriched diet improves renal function and reduces oxidative stress in metabolic syndrome animals: potential mechanism of TLR4-MAPK signaling pathway. PLoS ONE 2014, 9:e111976.
36. Elks C.M., Reed S.D., Mariappan N., Shukitt-Hale B., Joseph J.A., et al. A blueberry-enriched diet attenuates nephropathy in a rat model of hypertension via reduction in oxidative stress. PLoS One 2011, 6:e24028.
37. Freeman L.R., Zhang L., Nair A., Dasuri K., Francis J., et al. Obesity increases cerebrocortical reactive oxygen species and impairs brain function. Free Radic. Biol. Med. 2013, 56:226-233.
38. Peng H., Li W., Seth D.M., Nair A.R., Francis J., et al. (Pro)renin receptor mediates both angiotensin II-dependent and -independent oxidative stress in neuronal cells. PLoS One 2013, 8:e58339.
39. Schwartz S.M., Campbell G.R., Campbell J.H. Replication of smooth muscle cells in vascular disease. Circ. Res. 1986, 58:427-444.
40. Mujais S.K., Kauffman S., Katz A.I. Angiotensin II binding sites in individual segments of the rat nephron. J. Clin. Invest. 1986, 77:315-318.
41. Brown C.A., Zusman R.M., Haber E. Identification of an angiotensin receptor in rabbit renomedullary interstitial cells in tissue culture. Correlation with prostaglandin biosynthesis. Circ. Res. 1980, 46:802-807.
42. Johnson R.J., Alpers C.E., Yoshimura A., Lombardi D., Pritzl P., et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992, 19:464-474.
43. Homma T., Sakai M., Cheng H.F., Yasuda T., Coffey R.J., et al. Induction of heparin-binding epidermal growth factor-like growth factor mRNA in rat kidney after acute injury. J. Clin. Invest. 1995, 96:1018-1025.
44. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 2006, 69:73-80.
45. Bhaskaran M., Reddy K., Radhakrishanan N., Franki N., Ding G., et al. Angiotensin II induces apoptosis in renal proximal tubular cells. Am. J. Physiol. Renal Physiol. 2003, 284:F955-F965.
46. Schumer M., Colombel M.C., Sawczuk I.S., Gobe G., Connor J., et al. Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am. J. Pathol. 1992, 140:831-838.
47. Nouwen E.J., Verstrepen W.A., Buyssens N., Zhu M.Q., De Broe M.E. Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat. Lab. Invest. 1994, 70:479-493.
48. Wolf G., Bohlender J., Bondeva T., Roger T., Thaiss F., et al. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J. Am. Soc. Nephrol. 2006, 17:1585-1593.
49. Wolf G. Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. Antioxid. Redox Signal. 2005, 7:1337-1345.
50. Zhang J., Patel M.B., Griffiths R., Mao A., Song Y.S., et al. Tumor Necrosis Factor-alpha Produced in the Kidney Contributes to Angiotensin II-dependent Hypertension. Hypertension 2014.
51. Batal I., De Serres S.A., Mfarrej B.G., Grafals M., Pinkus G.S., et al. Glomerular inflammation correlates with endothelial injury and with IL-6 and IL-1beta secretion in the peripheral blood. Transplantation 2014, 97:1034-1042.
52. Wang Y., Li Y., Wu Y., Jia L., Wang J., et al. 5TNF-alpha and IL-1beta neutralization ameliorates angiotensin II-induced cardiac damage in male mice. Endocrinology 2014, 155:2677-2687.
53. Whiting C., Castillo A., Haque M.Z., Majid D.S. Protective role of the endothelial isoform of nitric oxide synthase in ANG II-induced inflammatory responses in the kidney. Am. J. Physiol. Renal Physiol. 2013, 305:F1031-F1041.
54. Sato W., Sato Y. Midkine in nephrogenesis, hypertension and kidney diseases. Br. J. Pharmacol. 2014, 171:879-887.
55. Smart M.L., Hiranyachattada S., Harris P.J. Effects of angiotensin II receptor blockade on proximal fluid uptake in the rat kidney. Br. J. Pharmacol. 1999, 126:697-700.
56. Kikuchi K., Tancharoen S., Ito T., Morimoto-Yamashita Y., Miura N., et al. Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int. J. Mol. Sci. 2013, 14:18899-18924.
57. Hagiwara S., Iwasaka H., Matumoto S., Hidaka S., Noguchi T. Effects of an angiotensin-converting enzyme inhibitor on the inflammatory response in in vivo and in vitro models. Crit. Care Med. 2009, 37:626-633.
58. Wilson C.B., McLaughlin L.D., Nair A., Ebenezer P.J., Dange R., et al. Inflammation and oxidative stress are elevated in the brain, blood, and adrenal glands during the progression of post-traumatic stress disorder in a predator exposure animal model. PLoS One 2013, 8:e76146.
59. Meng G., Liu Y., Lou C., Yang H. Emodin suppresses lipopolysaccharide-induced pro-inflammatory responses and NF-kappaB activation by disrupting lipid rafts in CD14-negative endothelial cells. Br. J. Pharmacol. 2010, 161:1628-1644.
60. Downes C.E., Crack P.J. Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?. Br. J. Pharmacol. 2010, 160:1872-1888.
61. Kandadi M.R., Frankel A.E., Ren J. Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy. Br. J. Pharmacol. 2012, 167:612-626.
62. Wilson C.B., McLaughlin L.D., Ebenezer P.J., Nair A.R., Francis J. Valproic acid effects in the hippocampus and prefrontal cortex in an animal model of post-traumatic stress disorder. Behav. Brain Res. 2014, 268:72-80.
63. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
64. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 1998, 2:253-258.
65. Muzio M., Natoli G., Saccani S., Levrero M., Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. 1998, 187:2097-2101.
66. Lamkanfi M., Sarkar A., Vande Walle L., Vitari A.C., Amer A.O., et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 2010, 185:4385-4392.
67. Fan J., Li Y., Levy R.M., Fan J.J., Hackam D.J., et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 2007, 178:6573-6580.
68. Tsoyi K., Jang H.J., Nizamutdinova I.T., Kim Y.M., Lee Y.S., et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br. J. Pharmacol. 2011, 162:1498-1508.
69. Tanaka J., Seki Y., Ishikura H., Tsubota M., Sekiguchi F., et al. Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats. Br. J. Pharmacol. 2013, 170:1233-1241.
70. Gan L.T., Van Rooyen D.M., Koina M., McCuskey R.S., Teoh N.C., et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J. Hepatol. 2014.
71. Zhang G., Chen F., Cao Y., Amos J.V., Shah G., et al. HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guerin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guerin. J. Urol. 2013, 190:1076-1082.
72. Rossini A., Zacheo A., Mocini D., Totta P., Facchiano A., et al. HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J. Mol. Cell. Cardiol. 2008, 44:683-693.